Worldwide Healthcare Trust - A mostly quiet summer month turned volatile in the back half of July. July factsheet 📰 - In July, the NAV per share total return was -1.2%, the share price total return was +1.1% and the MSCI World Health Care Index was +1.7%, on a net total return, sterling adjusted basis. - As U.S. tech stocks wobbled on quarterly earnings reports, it triggered a broader macro trade in which “crowded longs” and “retail favourites” were rapidly sold as investors instead rotated into value names and/or year-to-date laggards. ✅ A better-than-expected inflation report renewed hopes of interest rates cuts before the end of 2024. ✅ The top contributor was Daiichi Sankyo, which benefitted from a stellar quarterly earnings report at the month end (before a BoJ interest rate hike in Japan in early August disrupted the equity market there). ✅ Important contribution also came from healthcare services, as hospital provider Tenet Healthcare Corp and managed care provider UnitedHealth Group both reported better than expected quarterly results. ❌ On the negative side, “retail favourites” that sold off late in the month on no fundamental news included Eli Lilly and Company, Novo Nordisk, Boston Scientific, and Merck. ❌ Another key detractor was Dexcom, whose share price fell dramatically lower after a series of executional missteps lead to one of the worst quarterly reports the company has ever presided over. July factsheet: https://lnkd.in/eTna955M Find out more here: https://lnkd.in/eRNN7UZ6 Investments involve risks. The value of investments and income derived from them may go down as well as up and you may not receive back all the money which you invest. Past performance is no guarantee of future performance.
Worldwide Healthcare Trust’s Post
More Relevant Posts
-
2023 was a tough year for healthcare investing, resulting in the sector lagging the broader indices by the widest margin since 1999. We believe the outlook for 2024 is much more favourable as the sector’s valuation is highly compelling, while many of the headwinds are abating.
The healthcare sector experienced its widest margin lag against broader indices since 1999. But the outlook for 2024 looks promising. An industry wide recovery appears to be on the horizon as headwinds ease and the fundamental backdrop remains positive. Learn more: https://lnkd.in/e9ikRJY5
-
The healthcare sector experienced its widest margin lag against broader indices since 1999. But the outlook for 2024 looks promising. An industry wide recovery appears to be on the horizon as headwinds ease and the fundamental backdrop remains positive. Learn more: https://lnkd.in/e9ikRJY5
Healthcare investing - 2024 outlook brighter on compelling valuations and easing headwinds
viewpoint.bnpparibas-am.com
-
GLP-1 drugs became household names in 2023. But markets are pricing the shares for perfect execution. How often do we find a non biotech drug maker to be more richly valued than Nvidia? Not often! I hope you will give this Bloomberg article a quick read!
In this Bloomberg article, Managing Director and Portfolio Manager, Shams Afzal, AIF, provided his insights into healthcare versus the broader indexes going into 2024. “It very much remains the stock picker’s market…If the broader market rally continues, health care is going to do its fair share of heavy lifting to make up for 2023.” Subscribers can check out the story here: https://bloom.bg/41zqblF
Health Stocks Get Shot at Redemption After Ozempic-Fueled Losses
bloomberg.com
-
Business Development | Portfolio Management | Product Development | Project & Alliance Management | Corporate Strategy | HR
By 2030, 1 in 6 people globally will be over 60. In 2020, global healthcare expenditures hit an astonishing $9 trillion. And with the ageing population, this is just the tip of the iceberg, spurring unseen demand for healthcare services and innovations. Here’s something cool: I discovered that back in 2005, only about 5% of the new drugs in the U.S. were made just for certain people. Fast forward to 2022, and now it's 34%. That's a big jump, right? It shows that medicine is getting more and more personalised. With so many possibilities, how do we make the right choices in investments? It's all about mixing our knowledge of science with smart business thinking. For example, treatments for rare diseases might not be for a lot of people, but they can be really profitable because there's not much competition. They affect 1 in 10,000 people, yet the treatment for these can be profoundly lucrative due to the lack of competition and extended patent protection. According to me, it's not just about the science; it's also about understanding market mechanics. In a free price system like the U.S., balancing cost and profitability becomes crucial. And let's not forget in many developed countries, healthcare costs are largely covered by insurance and state funding, cushioning the market against economic fluctuations. So, it’s safe to say diversification is not just a strategy; it's a necessity. In investing, whether in advanced medical equipment or pioneering biotech firms, understanding the product lifecycle, market demand, and competitive landscape is vital. As we navigate these exciting yet complex waters, let’s remember our investments today shape the healthcare of tomorrow. Let’s make it count! #PharmaInvesting #HealthcareFuture #InnovationInPharma #LeadershipInHealthcare
-
-
The 2024 ZS Future of Health Report features perspectives from 9,500 individuals and nearly 1,400 healthcare providers in China, the U.S., Japan, Germany, the U.K. and Sweden. See what people across countries want from the healthcare system of the future. #FutureofHealth https://bit.ly/4aPfNdF
Future of healthcare insights: Health and patient experience | ZS
zs.com
-
The 2024 ZS Future of Health Report features perspectives from 9,500 individuals and nearly 1,400 healthcare providers in China, the U.S., Japan, Germany, the U.K. and Sweden. See what people across countries want from the healthcare system of the future. #FutureofHealth https://bit.ly/4aPfNdF
Future of healthcare insights: Health and patient experience | ZS
zs.com
-
In this Bloomberg article, Managing Director and Portfolio Manager, Shams Afzal, AIF, provided his insights into healthcare versus the broader indexes going into 2024. “It very much remains the stock picker’s market…If the broader market rally continues, health care is going to do its fair share of heavy lifting to make up for 2023.” Subscribers can check out the story here: https://bloom.bg/41zqblF
Health Stocks Get Shot at Redemption After Ozempic-Fueled Losses
bloomberg.com
-
BCG Principal | Solvandria Foundation Co-Founder | MIT Research Affiliate (PhD) | Caltech Alum (BS)
📣Our latest Boston Consulting Group (BCG) publication "The 2024 Outlook for Private Equity in US Health Care" is now available. Our expert author team draws on the experience of BCG’s entire health care practice to explore the trends that will have varying levels of impact across industry segments In 2024, the healthcare market's recovery is expected to reshape investment strategies across providers, payers, pharma, medtech, and life science tools, with a cautiously optimistic outlook for increased transaction volumes. Investors must navigate key challenges like labor supply, geopolitical turmoil, interest rates, inflation, and a tighter credit market, while considering the varied impact of these factors on different industry segments. 📖 Read the full article here: https://lnkd.in/dguTnWHd #HealthCareInvestment #PrivateEquity #2024Insights #InvestmentStrategies
-
-
Healthcare markets in the Asia-Pacific region are maturing—and in parallel, private equity deal volume is bucking the slowdown seen in North America. Our latest report breaks down the key factors behind India’s emergence as a new hub of healthcare PE deal activity.
India's Healthcare Industry Comes of Age
-
Healthcare markets in the Asia-Pacific region are maturing—and in parallel, private equity deal volume is bucking the slowdown seen in North America. Our latest report breaks down the key factors behind India’s emergence as a new hub of healthcare PE deal activity.
India's Healthcare Industry Comes of Age
